Showing results (11-20 of 15) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Oncologist|May 31, 2022
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER StudyMartina Lorenzi, Alessandra Ferro, Fabiana Cecere, et al.European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma IntergroupMarco Rubatto, Paolo Fava, Ignazio Stanganelli, et al.Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.Pageof 2